Notably, the cooperative effect of the low dose of ApoLNPs, tumor-exclusive administration by MSC guidance, and the cathepsin B-specific activation of the prodrug significantly lessened the systemic toxicity. The gene discussed is CTSB; the disease is neoplasm.